Mekonos Presentation: A Scalable Precision Delivery Platform for High Efficiency, High Viability ex-vivo Delivery into Difficult-To-Transfect Cells Using Silicon Nanoneedles
Friday, May 31, 2024 12:30 PM - 12:45 PM
Exhibit Hall - Theatre A
Global Showcase Presentation
Presenter
Mekonos is developing a novel ex vivo cell engineering technology which enables the delivery of any molecular cargo to any cell, supporting cell and gene therapy programs from the R&D stage through clinical and commercial manufacturing. We use silicon nanoneedles to enable high efficiency cargo delivery into the most fragile cells, including primary immune cells, and stem cells. Our unique chip architecture aligns single nanoneedles to individually trapped cells (“one needle per cell”), ensuring that each cell receives the same amount of cargo and resulting in a highly homogenous population of modified cells.
This novel approach enables single cell precision at scale and unlocks cell therapy applications which are unachievable with conventional delivery technologies, like electroporation and viral vectors. We will present data demonstrating how Mekonos' platform is uniquely positioned to enable advanced cell engineering capabilities such as: nuclear delivery; multiplexing and sequential editing; and dose control for delivering multiple components into cells with precision.
Showcase data on unique cell engineering applications enabled by the silicon nanoneedle chip platform:
• Nuclear delivery of plasmids in myeloid derived cells
• Manipulation of fragile cells (primary immune cells, stem cells) like HSCs, T cells, with high efficiency (70%+) and high viability (95%) of modified cells
• Multiplexed delivery of 3 different plasmids simultaneously
• Large cargo delivery (100kb+)
• Knockout in primary T cells using Cas9 RNP
• Dosage control to modulate gene expression level via changing delivery parameters
- Jake Lesnik, VP of Business Development, Mekonos, USA
Mekonos is developing a novel ex vivo cell engineering technology which enables the delivery of any molecular cargo to any cell, supporting cell and gene therapy programs from the R&D stage through clinical and commercial manufacturing. We use silicon nanoneedles to enable high efficiency cargo delivery into the most fragile cells, including primary immune cells, and stem cells. Our unique chip architecture aligns single nanoneedles to individually trapped cells (“one needle per cell”), ensuring that each cell receives the same amount of cargo and resulting in a highly homogenous population of modified cells.
This novel approach enables single cell precision at scale and unlocks cell therapy applications which are unachievable with conventional delivery technologies, like electroporation and viral vectors. We will present data demonstrating how Mekonos' platform is uniquely positioned to enable advanced cell engineering capabilities such as: nuclear delivery; multiplexing and sequential editing; and dose control for delivering multiple components into cells with precision.
Showcase data on unique cell engineering applications enabled by the silicon nanoneedle chip platform:
• Nuclear delivery of plasmids in myeloid derived cells
• Manipulation of fragile cells (primary immune cells, stem cells) like HSCs, T cells, with high efficiency (70%+) and high viability (95%) of modified cells
• Multiplexed delivery of 3 different plasmids simultaneously
• Large cargo delivery (100kb+)
• Knockout in primary T cells using Cas9 RNP
• Dosage control to modulate gene expression level via changing delivery parameters
SPONSORED BY:
